<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05082441</url>
  </required_header>
  <id_info>
    <org_study_id>IRB20-050</org_study_id>
    <nct_id>NCT05082441</nct_id>
  </id_info>
  <brief_title>Liposomal Bupivacaine in Benign Soft Tissue Tumor Resection</brief_title>
  <official_title>Efficacy of Liposomal Bupivacaine in Benign Soft Tissue Tumor Resection: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samaritan Health Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samaritan Health Services</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liposomal bupivacaine (Exparel) has been used as an adjunct to pain management in the&#xD;
      perioperative setting. However, the efficacy of the drug has not bewen studied in patients&#xD;
      with benign soft tissue tumor resections. The goal of the study is to see if Exparel controls&#xD;
      pain and improves functional outcomes for patients after these procedures compared to the&#xD;
      current standard Bupivacaine HCL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liposomal bupivacaine (Exparel) has been used as an adjunct to pain management in the&#xD;
      perioperative setting. However, the efficacy of the drug has not bewen studied in patients&#xD;
      with benign soft tissue tumor resections. The goal of the study is to see if Exparel controls&#xD;
      pain and improves functional outcomes for patients after these procedures compared to the&#xD;
      current standard Bupivacaine HCL.&#xD;
&#xD;
      Patients will be randomly assigned Exparel or Bupivacaine HCL intraoperatively during the&#xD;
      tumor resection. The amount administered is based on the size of wound after tumor resection.&#xD;
      The patients are then provided a pain diary in which they record the amount of pain&#xD;
      medications taken, VAS pain scores, and musculoskeletal and tumor society score (MSTS) for&#xD;
      the first week postoperatively.&#xD;
&#xD;
      The study will end once 140 patients have been enrolled. Data will be analyzed comparing&#xD;
      morphine equivalents, pain scores, and functional scores between the groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid Use</measure>
    <time_frame>first 7 days postoperatively</time_frame>
    <description>Amount of morphine equivalents used for postoperative pain control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Score</measure>
    <time_frame>First 7 days postoperatively</time_frame>
    <description>VAS pain score</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Musculoskeletal Tumor Society Score (MSTS score)</measure>
    <time_frame>First 7 days postoperatively</time_frame>
    <description>MSTS score postop compared to baseline</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Benign Neoplasm</condition>
  <arm_group>
    <arm_group_label>experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exparel group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>plain bupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine</intervention_name>
    <description>Exparel mixed with bupivacaine to be infiltrated in the subcutaneous region of the wound instead of plain bupivacaine</description>
    <arm_group_label>experimental</arm_group_label>
    <other_name>Experimental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Hydrochloride</intervention_name>
    <description>plain bupivacaine subcutaneous injection as standard of care control</description>
    <arm_group_label>control</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All benign soft tissue tumors greater than one cubic cm&#xD;
&#xD;
          -  Adults 18 years and older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant females&#xD;
&#xD;
          -  Women who are breastfeeding&#xD;
&#xD;
          -  Less than 18 years old&#xD;
&#xD;
          -  Malignant tumors&#xD;
&#xD;
          -  Tumors smaller than 1 cubic cm&#xD;
&#xD;
          -  Allergy to Exparel&#xD;
&#xD;
          -  Patients who are opioid dependent defined as patients on a long acting narcotic or who&#xD;
             take more than 30 morphine equivalents per day&#xD;
&#xD;
          -  Allergy to amide anesthetics&#xD;
&#xD;
          -  bone tumors&#xD;
&#xD;
          -  Patients unable to comply with the study standards and follow up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Good Samaritan Regional Medical Center</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jared Sanderford, DO</last_name>
      <phone>541-768-5111</phone>
      <email>jareds@samhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Nicolas Tedesco, DO</last_name>
      <phone>541-768-4811</phone>
      <email>ntedesco@samhealth.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Soft Tissue Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

